ADX10059 in migraine
In our Phase IIa clinical trial in 129 migraine patients, significantly more of the patients who received ADX10059 than those who received placebo were pain-free two hours after dosing (see Fig. 4). ADX10059 had better pain improvement than placebo at all time points up to two hours.
The results of the study suggest that mGluR5 inhibition might play a role in migraine therapy. As a result Addex intends to conduct further studies in migraine prevention to establish whether the compound has a role in this indication